BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2040 related articles for article (PubMed ID: 21958472)

  • 21. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis.
    Huang X; Yang J; Li J; Xiong Y
    Medicine (Baltimore); 2020 Aug; 99(35):e20932. PubMed ID: 32871859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
    Pennant M; Takwoingi Y; Pennant L; Davenport C; Fry-Smith A; Eisinga A; Andronis L; Arvanitis T; Deeks J; Hyde C
    Health Technol Assess; 2010 Oct; 14(50):1-103. PubMed ID: 21044553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accuracy of pre-operative 18-fluoride fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting lymph node involvement in colon cancer.
    Gauci CM; Kim TJ; Gao Y; Perera DS
    ANZ J Surg; 2023 Nov; 93(11):2675-2679. PubMed ID: 37530228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of whole-body [
    Mirshahvalad SA; Kohan A; Metser U; Hinzpeter R; Ortega C; Farag A; Veit-Haibach P
    Eur Radiol; 2024 Jan; 34(1):673-685. PubMed ID: 37535156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
    Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
    Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.
    Liu F; Zhang Q; Zhu D; Liu F; Li Z; Li J; Wang B; Zhou D; Dong J
    Medicine (Baltimore); 2015 Sep; 94(36):e1462. PubMed ID: 26356700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic performance of [
    Mirshahvalad SA; Hinzpeter R; Kohan A; Anconina R; Kulanthaivelu R; Ortega C; Metser U; Veit-Haibach P
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4205-4217. PubMed ID: 35705874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.
    Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC
    Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
    Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
    Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diagnostic performance of
    Samim M; Molenaar IQ; Seesing MFJ; van Rossum PSN; van den Bosch MAAJ; Ruers TJM; Borel Rinkes IHM; van Hillegersberg R; Lam MGEH; Verkooijen HM
    Surg Oncol; 2017 Mar; 26(1):37-45. PubMed ID: 28317583
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Gassert FG; Rübenthaler J; Cyran CC; Rink JS; Schwarze V; Luitjens J; Gassert FT; Makowski MR; Schoenberg SO; Mayerhoefer ME; Tamandl D; Froelich MF
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3268-3276. PubMed ID: 33686457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis.
    Lu YY; Chen JH; Chien CR; Chen WT; Tsai SC; Lin WY; Kao CH
    Int J Colorectal Dis; 2013 Aug; 28(8):1039-47. PubMed ID: 23407908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review.
    Maffione AM; Lopci E; Bluemel C; Giammarile F; Herrmann K; Rubello D
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):152-63. PubMed ID: 25319712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis.
    Burian E; Palla B; Callahan N; Pyka T; Wolff C; von Schacky CE; Schmid A; Froelich MF; Rübenthaler J; Makowski MR; Gassert FG
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3870-3877. PubMed ID: 35606526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.
    Goense L; van Rossum PS; Reitsma JB; Lam MG; Meijer GJ; van Vulpen M; Ruurda JP; van Hillegersberg R
    J Nucl Med; 2015 Jul; 56(7):995-1002. PubMed ID: 25952733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The optimal timing of FDG-PET/CT in non-small cell lung cancer diagnosis and staging in an Australian centre.
    Johnson A; Norman R; Piccolo F; Manners D
    BMC Pulm Med; 2021 Jul; 21(1):209. PubMed ID: 34210303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 102.